Pricing Log in Create free account
Friday 6 November 2026 Export SRTS’s income statement to Excel — free account

Sensus Healthcare, Inc.

SRTS Healthcare Medical Devices

Sensus Healthcare, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $27.5 million, down 34.3% from fiscal 2024.

Revenue
−68.7%
EPS
−783.3%
Free cash flow
−201.7%

Quarter to June 2026, against a year earlier

2.83 0.09 −3.08%
Market cap
$48.1M
P/E
0.0×
Fwd P/E
−3.5×
Dividend yield
—
F-score
4/9
Altman Z
8.85
Beneish M
−3.66
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.58
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — 1 — — 1 — — 5 — — —
Sell — — — — — — — — — — — —
Insider Ownership 18.66%

Capital & Financial Ratios $m

Size
Market Cap 48.07
Revenue ttm 17.51
Net income ttm (15.48)
Free cash flow ttm (6.97)
Net debt Q (15.19)
Valuation
P/E 0.00
Forward P/E (3.48) (negative: loss-making)
Price / sales 2.75
Forward P/S Powerpack
Price / FCF 0.00
Price / book 1.30
Financial health
Current ratio Q 8.71 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (6.84)
Growth
Revenue growth Q −68.69% (below 0%: shrinking)
Operating income growth Q −63.66% (below 0%: shrinking)
EPS, this year −68.62% (below 0%: weak)
EPS, next year A +85.80% (at or above 15%: strong)
Revenue, next year A −30.39% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A −5.59% (below 0%: weak)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.2×, against a ten-year median of 2.6×; over the ten years it ranged from 0.8× in 2023 to 6.9× in 2021.
P/S against its own 10 years 36.47%
10-year low 10-year high
P/B against its own 10 years 15.31%
10-year low 10-year high
EV/Sales against its own 10 years 35.23%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 23 22 22 15
Receivables 11 20 6 2
Inventory 15 13 16 19
Other — — — —
50 57 46 38
2023 2024 2025 Q'26
Payables 3 5 3 3
ST’ Debt — — — —
Other 1 0 0 0
4 6 5 4

Compound Annual Growth %

10y 5y 3y
Sales 10.34% 23.47% (14.86%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 23.30% 17.48% 0.02%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY25 Estimate −0.12 Actual −0.06

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY24 0.10 0.09 Miss by 0.01
Q1 FY25 0.04 −0.16 Miss by 0.20
Q2 FY25 0.01 −0.06 Miss by 0.07
Q3 FY25 −0.12 −0.06 Beat by 0.06

EPS $

Mar Jun Sep Dec Year
’26 (0.16) (0.53) — — —
’25 (0.16) (0.06) (0.06) (0.19) (0.47)
’24 0.14 0.10 0.07 0.09 0.41
’23 (0.12) (0.02) (0.09) 0.26 0.03
’22 0.97 0.21 0.11 0.17 1.46
’21 (0.07) (0.02) 0.01 0.32 0.25
’20 (0.22) (0.16) (0.10) 0.06 (0.42)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 3 2 — — —
’25 8 7 7 5 27
’24 11 9 9 13 42
’23 3 5 4 13 24
’22 10 12 9 13 45
’21 3 5 6 13 27
’20 2 1 2 5 10
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (4) (3) — — —
’25 (3) 3 2 (2) 1
’24 (8) 4 4 (1) (1)
’23 (6) 1 0 3 (2)
’22 3 2 4 (10) (1)
’21 (1) 1 1 (2) 0
’20 0 2 (3) 0 0
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (4) (3) — — —
’25 (3) 3 2 (2) 0
’24 (8) 4 4 (1) (1)
’23 (6) 1 0 3 (2)
’22 18 2 4 (10) 13
’21 (1) 2 1 (2) 0
’20 0 2 (3) 0 (1)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 15 21 26 27 10 27 45 24 42 27 18 +7.1% 19 28 35 +8.4%
Gross margin, % 66.48 67.03 63.99 64.40 54.81 62.82 66.53 57.61 58.44 43.18 36.39 (23.3) pt
EBT 0 (4) (2) (2) (7) 4 28 1 9 (10) (13) +44.7%
EBT margin, % (2.34) (18.02) (7.65) (6.24) (71.38) 15.23 62.85 2.67 21.58 (35.02) (72.53) (32.7) pt
Net income 0 (4) (2) (2) (7) 4 24 0 7 (8) (15) +41.2%
Per share, $
Per share, $ Revenue 1.23 1.56 1.87 1.68 0.58 1.64 2.70 1.50 2.56 1.68 1.06 +3.5%
Earnings (0.03) (0.28) (0.14) (0.10) (0.42) 0.25 1.47 0.03 0.41 (0.47) (0.94) +35.8%
Cash flow (0.07) (0.23) (0.61) (0.13) (0.03) (0.02) (0.09) (0.13) (0.05) 0.03 (0.41) n/m
Capex (0.02) (0.02) (0.06) (0.02) (0.02) 0.01 0.90 (0.01) (0.02) (0.01) (0.01) (7.3%)
Free cash flow (0.09) (0.25) (0.67) (0.15) (0.05) (0.01) 0.81 (0.14) (0.07) 0.02 (0.42) n/m
Book value 1.27 0.88 1.87 1.73 1.31 1.58 2.92 3.00 3.42 2.95 2.24 +9.8%
Shares, m 12 13 14 16 16 16 16 16 16 16 16 +3.5%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 30.08 4.83 83.00 17.30 0.00 0.00 13.5
P/S 4.26 3.66 3.96 2.11 6.62 4.40 2.61 1.66 2.70 2.36 2.75 3.4
P/B 4.13 6.46 3.95 2.05 2.95 4.57 2.42 0.83 2.02 1.35 1.30 3.1
EV/Sales 3.53 3.31 3.60 1.75 5.68 4.08 2.17 0.95 2.31 1.77 2.21 2.9
EV/FCF (46.02) (20.36) (10.09) (19.07) (68.56) (702.42) 7.19 (9.94) (87.32) 146.81 (5.56) (81.0)
Cash, $m
Cash, $m Operating cash flow (1) (3) (9) (2) 0 0 (1) (2) (1) 1 (7) n/m
Capex 0 0 (1) 0 0 0 15 0 0 0 0 (4.1%)
Free cash flow (1) (3) (9) (3) (1) 0 13 (2) (1) 0 (7) n/m
Balance, $m
Balance, $m Working capital 13 13 26 28 20 25 46 45 51 41 33 +13.6%
Net debt (12) (9) (15) (15) (15) (15) (26) (23) (22) (22) (15) +7.5%
Shareholders’ equity 15 12 26 28 21 26 48 49 56 48 37 +13.6%
Returns, %
Returns, % ROA (2.42) (19.64) (7.77) (4.84) (21.06) 13.67 54.50 0.88 11.47 (13.40) (30.94) (11.0) pt
ROIC (6.02) (85.89) (11.31) (9.83) (78.10) 22.40 41.11 (0.93) 14.97 (24.76) (38.22) (18.7) pt
ROE (3.27) (27.53) (10.61) (6.24) (27.62) 17.34 65.45 1.00 12.70 (14.85) (34.83) (11.6) pt
People
People Employees 37 45 48 53 42 37 42 35 54 60 — +5.5%
Revenue/emp, $m 0.40 0.46 0.55 0.51 0.23 0.73 1.06 0.70 0.77 0.46 — +1.5%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Sensus Healthcare, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
LNSR LENSAR, Inc. $67.6M 3.9× 6.9× +18.37% (above 0%: growing) n/m +96.81% (above 0%: growing) 59.27% 12.94% Compare
COCH Envoy Medical, Inc. $55.0M — (loss-making) — (loss-making) +57.14% (above 0%: growing) n/m −22.44% (below 0%: shrinking) (269.70%) (8,389.39%) Compare
SRTS Sensus Healthcare, Inc. $48.1M — (loss-making) — (loss-making) −68.69% (below 0%: shrinking) n/m −201.65% (below 0%: shrinking) 33.58% (138.86%)
MYO Myomo, Inc. $47.1M — (loss-making) — (loss-making) +21.26% (above 0%: growing) n/m +80.02% (above 0%: growing) 72.13% (19.26%) Compare
MDAI Spectral AI, Inc. $44.4M — (loss-making) — (loss-making) −30.42% (below 0%: shrinking) n/m −21.86% (below 0%: shrinking) 31.58% (122.70%) Compare
XTNT Xtant Medical Holdings, Inc. $42.1M — (loss-making) — (loss-making) −34.96% (below 0%: shrinking) n/m −881.96% (below 0%: shrinking) 57.88% (39.81%) Compare
CVRX CVRx, Inc. $39.2M — (loss-making) — (loss-making) −5.84% (below 0%: shrinking) n/m −9.91% (below 0%: shrinking) 86.74% (94.31%) Compare
TELA TELA Bio, Inc. $35.2M — (loss-making) — (loss-making) −4.49% (below 0%: shrinking) n/m −17.72% (below 0%: shrinking) 72.77% (48.12%) Compare
SNWV Sanuwave Health Inc. $19.4M 1.3× — (loss-making) −3.13% (below 0%: shrinking) n/m +86.75% (above 0%: growing) 76.23% (2.88%) Compare
Median of peers $43.3M — — −3.81% — −13.81% 65.70% (43.96%)

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 29 April 2026

Ownership

Directors and executive officers, together 10.20%
Edwin L. Solot, Jr. 7.60%
Joseph C. Sardano 7.30%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Sensus Healthcare, Inc. (SRTS) Latest News

20 Aug

Impact 3 · · The Motley Fool transcript

17 Aug

Impact 4 · transcript

14 Aug

Impact 3 · · Moby transcript

13 Aug

Impact 3 · · MarketBeat transcript
Impact 3 ·

20 May

Impact 4 · · Simply Wall St.

8 May

Impact 3 · · MarketBeat
Impact 3 · · Business Wire
Impact 3 · · Moby transcript

7 May

Impact 4 · · The Motley Fool transcript
Impact 4 · · Business Wire

27 Mar

Impact 3 · · Business Wire

11 Mar

Impact 3 · · Simply Wall St.

26 Feb

Impact 4 · · Business Wire

18 Feb

Impact 4 · · Business Wire

13 Feb

Impact 4 · · Moby transcript
Impact 3 · · GuruFocus.comGuruFocus.com transcript

12 Feb

Impact 4 · · MarketBeat transcript
Impact 4 · · The Motley Fool transcript
Impact 4 · · Business Wire
Impact 3 · · Simply Wall St.24/7 Wall St.Motley FoolBarchartMotley Fool24/7 Wall St.Motley FoolGOBankingRates

7 Jan

Impact 3 · · Business Wire

2 Jan

Impact 3 · · Simply Wall St.

23 Nov

Impact 3 · · Simply Wall St.

14 Nov

Impact 3 ·

12 Nov

Impact 3 · · Business Wire

9 Nov

Impact 3 · · Simply Wall St.

7 Nov

Impact 3 · · GuruFocus.com transcript

6 Nov

Impact 3 ·
Impact 3 · · Business Wire
stockrow.com/SRTS · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com